R&D channel feed

Pan­cre­at­ic can­cer study fail­ure crip­ples a Mer­ri­mack drug, forc­ing a coup de grâce and pipeline re­treat

7 years ago

Af­ter Ro­va-T bust, Ab­b­Vie plans new sol­id tu­mor as­sault, li­cens­ing next-gen CAR-T tech from Cal­i­br

7 years ago
Discovery

Roche’s Tecen­triq scoops up a big win in small cell lung can­cer, grab­bing the lead in front­line cas­es

7 years ago

Boehringer backs €20B R&D game plan with a $272M blue­print for new fa­cil­i­ty — 100 new hires

7 years ago
Financing

J&J opens up a new biotech in­cu­ba­tor, pol­ish­ing the Big Ap­ple's am­bi­tions to cre­ate a ma­jor hub

7 years ago
Startups
Pharma

Lat­est rank­ing of top re­search in­sti­tu­tions show Chi­na com­ing on strong — with sig­nif­i­cant im­pli­ca­tions for biotech

7 years ago
China

On a win­ning streak, Heron rock­ets up 30% on PhI­Ib pain drug da­ta

7 years ago

Mauled by a ma­jor set­back, In­cyte is point­ing to a bet­ter fu­ture — but con­cedes it al­so had to scrap an­oth­er failed study

7 years ago

No­vo Nordisk’s 'se­ma' whips Mer­ck’s di­a­betes drug ri­val in PhI­II as it reach­es for best-in-class rank­ing for GLP-1 group

7 years ago

Step right up: A biotech may soon sell an ex­per­i­men­tal med to dy­ing ALS pa­tients un­der 'Right to Try'

7 years ago
Bioregnum
Opinion

Bio­phar­ma ri­vals at Roche and Bay­er both stand to ben­e­fit from the trend to­ward in­creased test­ing of can­cer pa­tients

8 years ago

No­vo takes on gut-brain ax­is dis­cov­ery with Kally­ope, fo­cus­ing on obe­si­ty and di­a­betes

8 years ago
Pharma

GSK vs Gilead: Heavy­weight HIV fight will come down to a big show­down in Am­s­ter­dam next month

8 years ago

Ani­ka Ther­a­peu­tics shares crater as its 2nd PhI­II OA study flops -- drug com­bo pales in com­par­i­son to a steroid

8 years ago

Ver­tex ex­pands its San Diego R&D hub, adding a new wing for col­lab­o­ra­tors as it cen­ters on CF re­search

8 years ago
Financing

Build­ing up its rare obe­si­ty pipeline, Rhythm Phar­ma to raise $150M

8 years ago

Sarep­ta leads off Duchenne MD gene ther­a­py study with a ‘home run’ on ef­fi­ca­cy — but can they de­liv­er in 2 years?

8 years ago
Cell/Gene Tx

Valeant nose­dives on CRL for plaque pso­ri­a­sis, rais­ing con­cerns over tout­ed $1B pipeline

8 years ago
Pharma

Spin­raza ri­val? With DMD flops in the rearview mir­ror, PTC Ther­a­peu­tics posts strong SMA da­ta

8 years ago

Zio­pharm gets hit with a clin­i­cal hold as FDA red lights hu­man study us­ing their fast-built CAR-T

8 years ago

Cat­a­lyst Bio shares bashed as neu­tral­iz­ing an­ti­bod­ies force in­ves­ti­ga­tors to freeze he­mo­phil­ia co­hort work

8 years ago

Af­ter a crush­ing PhI­II fail­ure, Cy­to­ki­net­ics says its next-gen mus­cle drug is lin­ing up well in PhII — but big chal­lenges loom

8 years ago

Dai­ichi says it’s ready to change the stan­dard of care for acute myeloid leukemia — but it’s a work in progress

8 years ago

Win­ners and losers at #EHA18: Shares most­ly slide as da­ta from a range of promi­nent biotechs fail to wow in­vestors

8 years ago
First page Previous page 271272273274275276277 Next page Last page
A service from the Financial Times